BeOne Medicines Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BeOne Medicines (ONC) agreed with the U.S. government to exempt its pharmaceuticals from Section 232 tariffs in exchange for pricing commitments and $1B+ U.S. manufacturing investments, including a $300M expansion in New Jersey. The deal reduces tariff risk but may lower future product pricing.
BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.
President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
Over the past 7 days, alphai's AI scored 7 news stories mentioning BEIGF (BeOne Medicines Ltd.). Coverage has skewed bullish: 2 bullish, 4 neutral, and 1 bearish.
Recent BEIGF coverage spans regulation, corporate actions and technology.
In the last 30 days, BEIGF insiders filed 27 SEC Form 4 transactions — no purchases and 27 sales ($87.6M). The most active reporter was OYLER JOHN, Chief Executive Officer, with 24 filings. 96% of those filings were made under pre-arranged Rule 10b5-1 plans.
BeOne Medicines (ONC) agreed with the U.S. government to exempt its pharmaceuticals from Section 232 tariffs in exchange for pricing commitments and $1B+ U.S. manufacturing investments, including a $300M expansion in New Jersey. The deal reduces tariff risk but may lower future product pricing.
BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.
President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.
BeOne Medicines agreed to reduce the price of its esophageal cancer drug, Tevimbra, under the US Medicaid program. The company is one of nine to comply with the US government's Most Favored Nation drug pricing policy. Tevimbra accounts for 13% of BeOne's total revenue, with global sales reaching nearly CNY3 billion in H1 2024. The company's shares fell in Shanghai, Hong Kong, and New York.
alphai scores every news story that mentions BEIGF with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BeOne Medicines (ONC) agreed with the U.S. government to exempt its pharmaceuticals from Section 232 tariffs in exchange for pricing commitments and $1B+ U.S. manufacturing investments, including a $300M expansion in New Jersey. The deal reduces tariff risk but may lower future product pricing.
2 min readBeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.
2 min readPresident Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
3 min readPresident Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.
2 min readBeOne Medicines agreed to reduce the price of its esophageal cancer drug, Tevimbra, under the US Medicaid program. The company is one of nine to comply with the US government's Most Favored Nation drug pricing policy. Tevimbra accounts for 13% of BeOne's total revenue, with global sales reaching nearly CNY3 billion in H1 2024. The company's shares fell in Shanghai, Hong Kong, and New York.
2 min readNine drugmakers, including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), and Teva (TEVA), agreed to lower U.S. drug prices and invest $19.6B in U.S. factories. Shares showed mixed after-hours reactions. The deals follow earlier agreements with larger pharma companies, covering 89% of the branded drug market.
2 min readBeOne Medicines (Nasdaq: ONC) agreed with the U.S. Government to expand cancer medicine access and boost U.S. manufacturing. The company committed to pricing future FDA-approved products competitively and invested $300M in its NJ facility, adding 120 jobs. BeOne aims to enhance supply continuity and support its oncology pipeline.
1 min readBeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.
2 min readBeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Financial Information On August 26, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2026 Interim Report for the six months ended June 30, 2026 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock
2 min readBeOne Medicines (ONC) officer Xiaobin Wu plans to sell 15,000 ADS, acquired from RSU vesting between 2022 and 2023, according to a Form 144 filing. Wu sold 3,275 shares in June 2026, totaling $882,436.10. The sale is set for 2026 via Morgan Stanley.
1 min read
